Hepatitis B, ChronicPhase 2NCT00230490
Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201
A Phase 2 study testing pradefovir mesylate and adefovir dipivoxyl in people with Hepatitis B, Chronic, run by Bausch Health Americas, Inc..
Trial summary
Compare the long-term safety of pradefovir to adefovir dipivoxyl Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Hepatitis B, Chronic
- What is being tested?
- pradefovir mesylate and adefovir dipivoxyl
- How many people
- 150 participants
- Where
- No sites listed yet
- Study dates
- Jun 2005to May 2007
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Patients who completed 48 weeks of treatment in study RNA200103-201
Who cannot join
- Patients who were determined to be treatment failures in study RNA200103-201
- Patients who experienced a serious adverse event judged to be related to study drug in study RNA200103-201
- Patients with a serum creatinine greater than 2.0 mg/dl on two consecutive determinations in study RNA200103-201
About this study
Compare the long-term safety of pradefovir to adefovir dipivoxyl
Read the detailed description
- Compare the long-term safety of pradefovir to adefovir dipivoxyl
- Monitor development of resistance
- Evaluate virologic and biochemical response
- Conditions
- Hepatitis B, Chronic
- Being tested
- pradefovir mesylate, adefovir dipivoxyl
- Keywords
- Hepatitis B, Chronic, Hepatitis B Virus, Pradefovir Mesylate, Adefovir Dipivoxyl
- Medical subject headings
- Hepatitis B, Chronic, Hepatitis B
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
pradefovir mesylateDrug
adefovir dipivoxylDrug
What is being measured
The primary outcome is the main question the study is designed to answer.
- Safety: Clinical examinations of laboratory tests
- Efficacy: Change in viral load over time
Secondary outcomes (1)
- Efficacy: Proportion of patients with undetectable viral load
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Sep 2005 (estimated)
- Study startJun 2005
- Study completionMay 2007
Why it stopped: Adverse findings from nonclinical carcinogenicity studies.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hepatitis B, ChronicStudies of the same condition, open and under way.
- More trials run by Bausch Health Americas, Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 150 participants
Sponsor and investigators
- Lead sponsor
- Bausch Health Americas, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Ralph T. Doyle, Study director, Bausch Health Americas, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00230490
- Sponsor's protocol ID
- RNA200103-202
- Status last verified
- Nov 2019
- First submitted
- 28 Sep 2005
- Last updated
- 29 Nov 2019
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Nov 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201
- ClinicalTrials.gov ID
- NCT00230490
- Acronym / sponsor ID
- RNA200103-202
- Conditions
- Hepatitis B, Chronic
- Keywords
- Hepatitis B, Chronic, Hepatitis B Virus, Pradefovir Mesylate, Adefovir Dipivoxyl
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Adverse findings from nonclinical carcinogenicity studies.
- Enrolment
- 150 participants
- Lead sponsor
- Bausch Health Americas, Inc.Industry (pharma, biotech, devices)
- Study start
- Jun 2005
- Study completion
- May 2007 (actual)
- First posted
- 30 Sep 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Compare the long-term safety of pradefovir to adefovir dipivoxyl
Detailed description
- Compare the long-term safety of pradefovir to adefovir dipivoxyl
- Monitor development of resistance
- Evaluate virologic and biochemical response
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Patients who completed 48 weeks of treatment in study RNA200103-201
Key exclusion criteria (3 listed)
- Patients who were determined to be treatment failures in study RNA200103-201
- Patients who experienced a serious adverse event judged to be related to study drug in study RNA200103-201
- Patients with a serum creatinine greater than 2.0 mg/dl on two consecutive determinations in study RNA200103-201
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| pradefovir mesylate | Drug | – |
| adefovir dipivoxyl | Drug | – |
Primary outcome
- Safety: Clinical examinations of laboratory tests
- Efficacy: Change in viral load over time
1 secondary outcome
- Efficacy: Proportion of patients with undetectable viral load
Results and safety
The study was stopped early (reason given: Adverse findings from nonclinical carcinogenicity studies.). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Nov 2019.
Related trials for Hepatitis B, Chronic
Active, not recruitingPhase 4
Effectiveness of TAF in Reducing Clinical Events in CHB Patients Beyond Treatment Indications by Current Guidelines
Chronic Hepatitis b
Active, not recruitingPhase 4
Effectiveness of Antiviral Treatment in Cirrhotic Patients With Low-level Hepatitis B Virus DNA Levels
Hepatitis B, Chronic
RecruitingObservational study
Evaluation of Patients With Liver Disease
Hepatitis D, Hepatitis C
Not yet recruitingPhase 4
B-Ensure: Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants
Hepatitis B
RecruitingPhase 2
Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions
Hepatitis B, Chronic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ralph T. Doyle study director
Bausch Health Americas, Inc.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing pradefovir mesylate and adefovir dipivoxyl in people with Hepatitis B, Chronic, run by Bausch Health Americas, Inc..
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 29 Nov 2019. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early (reason given: Adverse findings from nonclinical carcinogenicity studies.). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
- Safety: Clinical examinations of laboratory tests. The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Nov 2019.